Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (MDNAF)
OTHER OTC:MDNAF
MDNAF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.70 - $2.20
Previous CloseN/A
Volume34.40K
Average Volume (3M)65.66K
Market Cap
C$69.75M
Enterprise Value$114.97M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Jun 25, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding78,215,750
10 Day Avg. Volume58,573
30 Day Avg. Volume65,655
Standard Deviation0.35
R-Squared0.06
Alpha0.00684
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.01Price Target Upside366.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Medicenna Therapeutics Corp News
PremiumCompany Announcements
Medicenna to Engage Investors at February 2025 Conferences
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promise in Cancer Treatment
PremiumCompany Announcements
Medicenna’s MDNA11 Shows Promising Cancer Treatment Results
PremiumCompany Announcements
Medicenna Unveils New Data on Cancer Treatment
PremiumCompany Announcements
Medicenna’s Innovative Cancer Therapies Show Promise
PremiumCompany Announcements
Medicenna Showcases Promising Results and Strong Financials---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsInitial safety data has led to the approval for enrollment of higher dose cohorts, indicating a promising outlook for further trials.
Financial StabilityThe cash runway for Medicenna Therapeutics extends into mid-calendar 2026, supporting its financial stability.
Bears Say
Efficacy ConcernsAlthough the combo data is promising, it is too early to determine efficacy.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.07% Insiders
0.15% Other Institutional Investors
84.78% Public Companies and
Individual Investors
MDNAF FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was $0.69 and its highest was $2.20 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Medicenna Therapeutics Corp’s market cap is C$69.75M.
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Jun 25, 2025 which is in 123 days.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Feb 13, 2025. The company reported -$0.049 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.005.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate is -0.04.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 78,215,750 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -$0.049 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went up 6.818%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in MDNAF
---
Medicenna Therapeutics Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.01 (366.41% Upside)
$4.01 (366.41% Upside)
Blogger Sentiment
Bullish
MDNAF Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth C$90.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.12%
12-Months-Change
Fundamentals
Return on Equity
-149.09%
Trailing 12-Months
Asset Growth
38.55%
Trailing 12-Months
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.
---
MDNAF Stock 12 Month Forecast
Average Price Target
$4.01
▲(366.41% Upside)
Technical Analysis
Best Analysts Covering MDNAF
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
+32.62%
reiterated a buy rating 3 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of +32.62% per trade.
---